These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 23975081)

  • 21. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group.
    Marnitz S; Martus P; Köhler C; Stromberger C; Asse E; Mallmann P; Schmidberger H; Affonso Júnior RJ; Nunes JS; Sehouli J; Budach V
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):243-53. PubMed ID: 26853333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk stratification for failure in patients with advanced cervical cancer after concurrent chemoradiotherapy: another way to optimise treatment results.
    Liang JA; Chen SW; Chang WC; Hung YC; Yeh LS; Yang SN; Lin FJ
    Clin Oncol (R Coll Radiol); 2008 Nov; 20(9):683-90. PubMed ID: 18676129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of elective para-aortic lymph node irradiation in patients with locally advanced cervical cancer.
    Yap ML; Cuartero J; Yan J; Pintilie M; Fyles A; Levin W; Manchul L; Milosevic M
    Clin Oncol (R Coll Radiol); 2014 Dec; 26(12):797-803. PubMed ID: 25194726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of failure after use of (18)F-FDG PET/CT in integration of extended-field chemo-IMRT and 3D-brachytherapy plannings for advanced cervical cancers with extensive lymph node metastases.
    Chung YL; Horng CF; Lee PI; Chen FL
    BMC Cancer; 2016 Mar; 16():179. PubMed ID: 26940959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer.
    Beriwal S; Gan GN; Heron DE; Selvaraj RN; Kim H; Lalonde R; Kelley JL; Edwards RP
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):166-71. PubMed ID: 17321070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Feasibility of extended-field irradiation and intracavitary brachytherapy combined with weekly cisplatin chemosensitization for IB2-IIIB cervical cancer with positive paraaortic or high common iliac lymph nodes: a retrospective review.
    Kuji S; Hirashima Y; Komeda S; Tanaka A; Abe M; Takahashi N; Takekuma M; Asakura H; Harada H; Nishimura T
    Int J Clin Oncol; 2014 Apr; 19(2):341-7. PubMed ID: 23546545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study.
    Gandhi AK; Sharma DN; Rath GK; Julka PK; Subramani V; Sharma S; Manigandan D; Laviraj MA; Kumar S; Thulkar S
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):542-8. PubMed ID: 24074927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose extended-field irradiation and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic lymph nodes.
    Kim YS; Kim JH; Ahn SD; Lee SW; Shin SS; Nam JH; Kim YT; Kim YM; Kim JH; Choi EK
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1522-8. PubMed ID: 19231106
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).
    Toita T; Kitagawa R; Hamano T; Umayahara K; Hirashima Y; Aoki Y; Oguchi M; Mikami M; Takizawa K;
    Int J Gynecol Cancer; 2012 Oct; 22(8):1420-6. PubMed ID: 22932262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes for patients with cervical cancer treated with extended-field intensity-modulated radiation therapy and concurrent cisplatin.
    Jensen LG; Hasselle MD; Rose BS; Nath SK; Hasan Y; Scanderbeg DJ; Yashar CM; Mundt AJ; Mell LK
    Int J Gynecol Cancer; 2013 Jan; 23(1):119-25. PubMed ID: 23262521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maximum Standardized Uptake Value of Pelvic Lymph Nodes in [18F]-Fluorodeoxyglucose Positron Emission Tomography Is a Prognostic Factor for Para-Aortic Lymph Node Recurrence in Pelvic Node-Positive Cervical Cancer Treated With Definitive Chemoradiotherapy.
    Kim DH; Kim WT; Bae JS; Ki YK; Park D; Suh DS; Kim KH; Lee JH; Lee JY; Jeon HS; Nam JH
    Int J Gynecol Cancer; 2016 Sep; 26(7):1274-80. PubMed ID: 27465890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical efficacy and toxicity of radio-chemotherapy and magnetic resonance imaging-guided brachytherapy for locally advanced cervical cancer patients: A mono-institutional experience.
    Lakosi F; de Cuypere M; Viet Nguyen P; Jansen N; Warlimont B; Gulyban A; Gennigens C; Seidel L; Delbecque K; Coucke P; Hermesse J; Kridelka F
    Acta Oncol; 2015; 54(9):1558-66. PubMed ID: 26406152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Outcomes and prognostic factors of advanced squamous cervical cancer after concurrent chemoradiotherapy].
    Binbin T; Lingying W; Manni H; Jusheng A; Ning L
    Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):348-54. PubMed ID: 25030731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neo-adjuvant platinum-based chemotherapy followed by chemoradiation and radical surgery in locally advanced cervical cancer (Lacc) patients: A phase II study.
    Ferrandina G; Palluzzi E; Gallotta V; Gambacorta MA; Autorino R; Turco LC; Macchia G; Cosentino F; Gui B; Mattoli MV; Ronzino G; Valentini V; Scambia G
    Eur J Surg Oncol; 2018 Jul; 44(7):1062-1068. PubMed ID: 29753611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
    Chung YL; Jian JJ; Cheng SH; Hsieh CI; Tan TD; Chang HJ; Hung CF; Horng CF; Soong T; Tsou MH
    Gynecol Oncol; 2005 Apr; 97(1):126-35. PubMed ID: 15790448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Definitive extended-field intensity-modulated radiotherapy with chemotherapy for cervical cancer with para-aortic nodal metastasis.
    Jung J; Park G; Kim YS
    Anticancer Res; 2014 Aug; 34(8):4361-6. PubMed ID: 25075072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical study of intensity modulated radiotherapy and three-dimensional conformal radiotherapy with three-dimensional brachytherapy and concurrent chemotherapy for patients with advanced cervical cancer].
    Du XX; Yang H; Zhang HJ; Li LA; Fan WS; Meng YG
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):679-686. PubMed ID: 29060966
    [No Abstract]   [Full Text] [Related]  

  • 38. Optimal Extent of Prophylactic Irradiation of Paraaortic Lymph Nodes in Patients with Uterine Cervical Cancer.
    Choi J; Yoon HI; Lee J; Keum KC; Kim GE; Kim YB
    PLoS One; 2015; 10(12):e0145158. PubMed ID: 26659867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Treatment Time on Chemoradiotherapy in Locally Advanced Cervical Carcinoma.
    Pathy S; Kumar L; Pandey RM; Upadhyay A; Roy S; Dadhwal V; Madan R; Chander S
    Asian Pac J Cancer Prev; 2015; 16(12):5075-9. PubMed ID: 26163644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20.
    Rotman M; Pajak TF; Choi K; Clery M; Marcial V; Grigsby PW; Cooper J; John M
    JAMA; 1995 Aug; 274(5):387-93. PubMed ID: 7616634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.